Ghrelin, a novel 28 amino acid peptide, was initially purified from rat stomach (Kojima et al. 1999 ) and localized to gastric oxyntic glands (Date et al. 2000a) , the hypothalamic arcuate nucleus (Kojima et al. 1999 ) and kidney . In common with synthetic growth hormone secretagogues (GHSs), ghrelin causes growth hormone release in humans and rats following either peripheral or central administration, and from primary cultured pituitary cells (Kojima et al. 1999; Takaya et al. 2000; Wren et al. 2000; Date et al. 2000b) . In rats, ghrelin has been found to stimulate food intake (Wren et al. 2000; Nakazato et al. 2001) , to induce adiposity (Tschop et al. 2000) and to increase body weight (Tschop et al. 2000; Nakazato et al. 2001) , suggesting a possible role in regulation of feeding behaviour and energy metabolism. In addition, ghrelin has been recently reported to stimulate gastric acid secretion and gastric motility in anaesthetized rats (Masuda et al. 2000; Date et al. 2001 ).
The latter observation suggests that ghrelin may regulate gastrointestinal function.
Pancreatic exocrine secretion is controlled physiologically by both the autonomic nervous system and a number of brain-gut peptides. Among these peptides, cholecystokinin (CCK), secretin and cocaine-and amphetamine-regulated transcript peptide (CART) have been reported to stimulate pancreatic secretion (Chey, 1993; Cowles et al. 2001) , whereas neuropeptide Y and somatostatin serve as inhibitors (Mulholland et al. 1991; Chey, 1993) . The present study was performed to examine the effect of ghrelin on pancreatic exocrine function in anaesthetized rats. The present authors sought to (1) demonstrate an in vivo inhibitory effect of ghrelin on exocrine pancreatic secretion stimulated by CCK, 2-deoxy-D-glucose (2-DG), or bethanechol; and (2) determine the in vitro effects of ghrelin on amylase release from purified pancreatic acini and pancreatic lobules. demonstrated no inhibition of CCK-stimulated amylase release from dispersed acini. In contrast, ghrelin (10
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_9
-10 _7 M) dose-dependently inhibited amylase release from pancreatic lobules exposed to 75 mM potassium.
6. Our results show that (1) ghrelin is a potent inhibitor of pancreatic exocrine secretion in anaesthetized rats in vivo and in pancreatic lobules in vitro; and (2) the actions of ghrelin are indirect and may be exerted at the level of intrapancreatic neurons.
On the morning of the experiment, rats were anaesthetized with intramuscular injection of a mixture of xylazine and ketamine (13 and 87 mg (kg body weight) _1 , respectively). Supplemental doses were used every 2 h as needed to maintain adequate anaesthesia. An intravenous cannula was placed into the right external jugular vein for infusion of 0.9 % NaCl (1 ml h _1 ) and other chemicals. Through an upper midline laparotomy, the duodenum was elevated and the bile-pancreatic duct isolated as it entered the posterior duodenum. Through a small incision, a polyethylene cannula (PE10) was advanced into the bile-pancreatic common duct and was secured in place with fine silk suture. A second polyethylene cannula (PE50) was placed into the duodenum and its tip secured proximal to the ampulla for infusion of previously harvested bile-pancreatic juice. The abdominal wound was covered with a saline-moist gauze and the rats were maintained at 37°C with a thermal barrier. At the end of experiments, animals were killed by CO 2 inhalation and cervical dislocation.
Pancreatic secretion study. Secreted bile-pancreatic juice was collected for 45 min prior to starting the experiments to allow for stabilization of flow following surgical manipulation. Bilepancreatic secretions were collected over 15 min periods. Volume was recorded and aliquots assayed for protein content. Previously collected bile-pancreatic juice was re-infused via the duodenal cannula at the rate of 1.2 ml h _1 . Protein measurements were made using the Bio-Rad protein assay kit.
CCK-8 stimulation. CCK-8 was infused continuously at a rate of 400 pmol kg _1 h _1 for 90 min. Preliminary studies determined that this produced submaximal stimulation of pancreatic secretion. Infusions of synthetic rat ghrelin (1.2 or 12 nmol kg _1 h _1 ) were begun 15 min before CCK-8 administration and continued for the remainder of the experiment.
2-DG stimulation. 2-DG was dissolved in saline and administered as a bolus intravenous injection at the end of the basal collection period. Ghrelin infusion (12 nmol kg _1 h _1 ) was started 15 min before 2-DG injection and continued for the remaining time of the experiment.
Bethanechol stimulation. Bethanechol was dissolved in saline and administered as a continuous intravenous infusion beginning at the end of the basal collection period. Ghrelin infusion (12 nmol kg _1 h _1 ) was begun 15 min before the bethanechol infusion and continued for the rest of the experiment.
Subdiaphragmatic vagotomy. Through a midline laparotomy, the oesophagus was exposed. Subdiaphragmatic vagal trunks were exposed halfway between the diaphragm and the gastric cardia and both anterior and posterior trunks were transected.
Dispersed acini studies Preparation of acinar cells. Preparation of dispersed rat pancreatic acini was performed according to Williams et al. (1978) . Briefly, rats that had been fasted overnight were killed by CO 2 inhalation, and the pancreata were removed and placed in a Petri dish containing fresh Krebs-Ringer buffer (KRB) solution consisting of (mM): 110 NaCl, 0.5 CaCl 2 , 1.1 MgCl 2 , 4.7 KCl, 0.55 Na 2 HPO 4 , 32.5 NaHCO 3 , 22 glucose, 2 glutamine, 0.1 mg ml _1 soybean trypsin inhibitor and 1 % (v/v) Eagle's minimal essential amino acids, equilibrated with 5 % CO 2 -95 % O 2 , adjusted to pH 7.4. After fat and lymphatic tissue were trimmed away, each pancreas was digested with collagenase, mechanically dispersed, and passed through a 150 µm mesh nylon cloth. Acini were purified by centrifugation at 50 g for 3 min in KRB solution containing 4 % BSA, and resuspended in incubation buffer that consisted of Hepes buffered Ringer (HRB) solution containing (mM): 127 NaCl, 1.28 CaCl 2 , 0.55 MgCl 2 , 4.7 KCl, 0.55 Na 2 HPO 4 , 10 Hepes, 11 glucose, 2 glutamine, 1 % (v/v) Eagle's minimal essential amino acids, 0.1 mg ml _1 soybean trypsin inhibitor and 10 mg ml _1 BSA, oxygenated with 100 % O 2 , and adjusted to pH 7.4.
Amylase assay. Acini were pre-incubated at 37°C with minimal shaking for 60 min, followed by treatment with different agonists in 1 ml aliquots in polystyrene vials for the indicated times. Acini were then pelleted. The acinar cells contained within the pellet were lysed with a sonicator for 15 s. Amylase content in both the pellet and the supernatants was determined using the Phadebas reagent and expressed as a percentage of total cellular amylase content.
Pancreatic lobule studies
Pancreatic lobules, containing intrapancreatic nerve terminals and islets in addition to exocrine cells, were prepared by the method of Scheele & Palade (1975) . Fasted rats were killed by CO 2 inhalation and pancreata were removed. After trimming away peripancreatic fat and lymph nodes, the pancreatic tissue was divided into 4 mm w 5 mm lobular units; lobules were placed in KrebsHenseleit-bicarbonate (KHB) solution containing (mM): 110 NaCl, 1.8 CaCl 2 , 1.1 MgCl 2 , 4.7 KCl, 1.1 Na 2 HPO 4 , 25 NaHCO 3 , 25 Hepes, 11 glucose, 2 glutamine, 0.1 mg ml _1 soybean trypsin inhibitor, and 1 % (v/v) Eagle's minimal essential amino acids, equilibrated with 5 % CO 2 -95 % O 2 , and adjusted to pH 7.4. Lobules were allowed to recover for 30 min at 37°C. Lobular tissues were then exposed to the agonist with or without the presence of graded concentrations of ghrelin for 30 min. The medium was then aspirated, diluted 1:10 and assayed for amylase. To the remaining tissue, 1 ml KHB was added and the tissue was homogenized. Tissue homogenates were then assayed for amylase. Amylase released was expressed as the percentage of total tissue content.
Statistical analysis
Data were expressed as multiples of basal secretion. The results are expressed as means ± S.E.M. A two-way analysis of variance (ANOVA) was used to analyse differences between treatment groups. Integrated protein output was calculated by cumulative protein secretion during the time in which both ghrelin and agonists were infused. Student's unpaired t test was used to analyse data from integrated protein secretion, volume and amylase output, and from dispersed acinar cell and pancreatic lobule preparations. Differences were considered significant when P values were less than 0.05.
RESULTS
Effects of ghrelin on basal pancreatic secretion
Basal secretion was averaged from three 15 min collections of bile-pancreatic juice prior to the application of tested agents. The volume of basal secretion averaged 0.33 ± 0.02 ml per 15 min (n = 6). Basal pancreatic protein secretion averaged 3.2 ± 0.8 mg h _1 . Basal amylase release was 3.7 ± 0.5 U min _1 . Ghrelin infusion (12 nmol kg _1 h _1 ) had no significant effect upon basal secretory volume, protein or amylase outputs.
Effects of ghrelin on CCK-stimulated pancreatic secretion CCK-8 was infused at a rate of 400 pmol kg _1 h _1 , which was chosen to stimulate submaximal pancreatic secretion (Schonfeld et al. 1989) . Pancreatic protein output increased significantly above basal levels by 15 min, reaching peak values at 45 min, and remained significantly elevated for the duration of the study (Fig. 1) . The average volume of bile-pancreatic juice increased from 0.32 ± 0.03 to 0.38 ± 0.04 ml per 15 min (n = 6, P < 0.05). Ghrelin was infused at two doses (1.2 and 12 nmol kg _1 h _1 ), beginning 15 min before initiation of CCK-8 infusion. These doses of ghrelin were chosen based on the studies in which ghrelin significantly increased food intake in rats (Tschop et al. 2000; Wren et al. 2000) or stimulated gastric acid secretion (Masuda et al. 2000) . Significant and dose-related inhibition of CCK-8-stimulated protein secretion was observed (Fig. 1) 
Effects of ghrelin on CCK-stimulated pancreatic secretion in rats with acute vagotomy
When subdiaphragmatic vagotomy was performed acutely, ghrelin (12 nmol kg _1 h _1 ) retained the ability to inhibit CCK (400 pmol kg _1 h _1 )-induced increase in pancreatic protein secretion by 75 ± 18 % (P < 0.05, n = 6; Fig. 2 ).
Effects of ghrelin on 2-DG-stimulated pancreatic secretion 2-DG is a well-characterized centrally acting vagal stimulant (Becker et al. 1988; Putnam et al. 1989) . Infusion ) in acutely vagotomized rats Subdiaphragmatic vagotomy was performed prior to beginning measurements. Ghrelin (12 nmol kg _1 h _1 ) was infused continuously from 45 to 150 min. CCK infusion was begun at 60 min in both groups. For both groups, n = 6 (two-way ANOVA, P < 0.05).
of ghrelin was begun 15 min before 2-DG administration (75 mg kg _1 ) (Fig. 3) . Ghrelin at 12 nmol kg _1 h _1 abolished 2-DG-stimulated pancreatic secretion.
Effects of ghrelin on bethanechol-stimulated pancreatic secretion
The effects of ghrelin on cholinergically stimulated pancreatic secretion were studied by using bethanechol, a muscarinic receptor agonist without significant nicotinic receptor effect (Putnam et al. 1989) . Bethanechol at an infusion rate of 3 mg kg _1 h _1 stimulated pancreatic protein secretions by 5 ± 0.9-fold at 45 min (n = 6, P < 0.05; Fig. 4) . Infusion of ghrelin at a rate of 12 nmol kg _1 h _1 decreased integrated bethanecholstimulated pancreatic protein secretion by 59 ± 7 % (P < 0.05).
In vitro effects of ghrelin
To test for a direct inhibitory effect of ghrelin on pancreatic exocrine function, dispersed acinar cells were incubated with various doses of the peptide in vitro. Ghrelin alone produced no significant change in basal amylase release (Fig. 5) . Co-incubation of CCK-8 (10
with various concentrations of ghrelin produced no alteration in amylase release compared to that observed with CCK-8 alone (Fig. 5) .
Incubation of pancreatic lobules in a medium containing elevated potassium (75 mM) significantly increased amylase release. Ghrelin, at concentrations from 10 _9 to 10 _7 M, dose-dependently decreased amylase release from pancreatic lobules that were exposed to potassium (Fig. 6) .
DISCUSSION
The present study supports the concept that ghrelin inhibits pancreatic secretion via a mechanism involving the intrapancreatic nervous system. This contention is supported by the following six pieces of evidence: (1) ghrelin significantly inhibited CCK-stimulated pancreatic secretion in vivo; (2) ghrelin inhibited CCKstimulated pancreatic secretion in rats with acute vagotomy; (3) continuous infusion of ghrelin abolished pancreatic secretion stimulated by 2-DG; (4) pancreatic secretion stimulated by bethanechol was only partially attenuated by infusion of ghrelin; (5) ghrelin demonstrated no direct effect on the basal and CCK-stimulated amylase release in dispersed acinar cells; and (6) ghrelin blocked potassium-induced amylase release from pancreatic lobules in vitro.
Ghrelin is a novel 28 amino acid peptide secreted from the endocrine cells of gastric mucosa (Kojima et al. 1999) . It is an endogenous ligand for the growth hormone secretagogue (GHS) receptor, which has been demonstrated in both the central nervous system and peripheral tissues (Howard et al. 1996; Guan et al. 1997; Papotti et al. 2000) . Whereas ghrelin was initially identified as a growth-hormonereleasing peptide, a broader array of actions have recently been reported. Expression of ghrelin and its related receptor, GHS receptor, in kidney indicates that ghrelin may play an important role in the regulation of renal function . Stimulation of food intake and subsequent body weight gain have been demonstrated in rats administered ghrelin either centrally or peripherally (Tschop et al. 2000; Wren et al. 2000; Nakazato et al. 2001) . In the gastrointestinal system, ghrelin has been demonstrated to regulate gastric acid secretion and gastric motility (Masuda et al. 2000; .
That ghrelin may be involved in regulation of digestive processes is supported by the observation that ghrelinproducing cells correspond to X/A-like endocrine cells in the gastrointestinal tracts of rats and humans identified by light and electron microscopic immunohistochemistry and by in situ hybridization (Date et al. 2000a) . Ghrelin receptor (GHS receptor) mRNA has also been identified in the gastrointestinal tract including stomach, small intestine and pancreas (Guan et al. 1997; Date et al. 2000a) . While the pancreas has been demonstrated to express GHS receptor by RT-PCR (Guan et al. 1997) , the functional response to ghrelin has not previously been reported. The present studies demonstrate that ghrelin is a potent inhibitor for stimulated pancreatic protein secretion in vivo. As a result of rapid degradation in serum, relatively high doses are required during peripheral administration of ghrelin to achieve concentrations equivalent to postprandial blood levels (Tschop et al. 2000) . The doses used in our studies correspond to those reported by Tschop et al. (2000) and Wren et al. (2000) to increase food intake in rats.
Regulation of pancreatic exocrine secretion occurs at multiple levels, including the central nervous system, pancreatic innervation, intrapancreatic neurons and via receptors on pancreatic acinar cells. While ghrelin inhibited pancreatic protein output in vivo, the effect was indirect because ghrelin did not have an effect when dispersed pancreatic acini were exposed to the peptide in vitro. These in vitro studies strongly suggest that the inhibitory actions of ghrelin are not mediated by direct actions on the acinar cells. Similar indirect inhibitory action on pancreatic secretions has been reported for neuropeptide Y (NPY; Mulholland et al. 1991) . Similar to NPY, ghrelin appears to act on the intrapancreatic neurons to inhibit pancreatic protein secretion.
Several recent reports suggest that ghrelin acts within the central nervous system. Ghrelin up-regulates the expression of c-fos, NPY and agouti-related protein (AGRP) genes in hypothalamus (Hewson & Dickson, 2000; Kamegai et al. 2000; Nakazato et al. 2001 ) and c-fos mRNA expression in dorsomotor nucleus of the vagus . Stimulation of gastric secretion by ghrelin administered by intracerebroventricular injection is mediated by direct central activation of a central vagal mechanism . Three observations from the present study support the idea that the actions of ghrelin on pancreatic secretion are directed at the level of intrapancreatic neurons. First, ghrelin abolished pancreatic protein secretion stimulated by 2-DG, a centrally acting vagal stimulant, but only partially inhibited pancreatic protein secretion stimulated by CCK or bethanechol. Secondly, vagotomy failed to reverse the inhibitory effects of ghrelin on CCK stimulation of pancreatic secretion. Thirdly, ghrelin dose-dependently decreased amylase release stimulated by depolarizing concentration of KCl in pancreatic lobules. 
